---
title: "Ventripoint Issues Option Grants and Reports Exercise of Options"
date: "2025-02-12 05:55:10"
summary: "(TheNewswire)Toronto, Ontario – TheNewswire– February 11, 2024 - VentripointDiagnostics Ltd. (“Ventripoint ” or the “ Corporation ”)(TSXV:VPT, OTC:VPTDF) announces that on January 20,2025, the Corporation granted an aggregate of 4,015,000 options todirectors, officers, employees, contractors and consultants of theCorporation with an exercise price of $0.10 and terms of between 2(two)..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

(TheNewswire)




Toronto, Ontario – TheNewswire– February 11, 2024 - VentripointDiagnostics Ltd. (“Ventripoint ” or the “ Corporation ”)(TSXV:VPT, OTC:VPTDF) announces that on January 20,2025, the Corporation granted an aggregate of 4,015,000 options todirectors, officers, employees, contractors and consultants of theCorporation with an exercise price of $0.10 and terms of between 2(two) to 10 (ten) years, vesting from immediately to over a 3 (three)year period. Of these option grants, 200,000 were awarded to directorsand an additional 325,000 were awarded to officers some of which arealso directors of the Corporation.

These annual option grants are an important part ofincentivizing stakeholders to drive value in the Corporation.

Since the last update (see NR September 9, 2024),a total of 153,200 options were exercised with aweighted average price of approximately $0.13 per share for grossproceeds to the Corporation of $19,310.  There are currently11,762,750 option grantsoutstanding with exercise prices between $0.10 to $0.50 with aweighted average price of $0.21, and8,652,750 of these options have vested.

The Corporation has 3,231,641options available for future grants under theStock Option Plan as approved by shareholders at the last Special andAnnual General Meeting of the Corporation on November 1, 2023.

For further information, pleasecontact:

Hugh MacNaught

President and CEO

hmacnaught@ventripoint.com

(604) 671-4201

Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.

About Ventripoint DiagnosticsLtd.

Ventripoint has become an industry leader in the application of AI(Artificial Intelligence) to echocardiography. Ventripoint's VMSproducts are powered by its proprietary KBR technology, which is theresult of a decade of development and provides accurate volumetriccardiac measurements equivalent to MRI. This affordable, gold-standardalternative allows cardiologists greater confidence in the managementof their patients. Providing better care to patients serves as aspringboard and basic standard for all Ventripoint's products thatguide our future developments. In addition, VMS+ is versatile and canbe used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe, and Canada.

Forward Looking Statements

This news release contains forward-looking statements andforward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.

Since forward-looking statements and information address future eventsand conditions, by their very nature they involve inherent risks anduncertainties. Actual results could differ materially from thosecurrently anticipated due to several factors and risks. Factors whichcould materially affect such forward-looking information are describedin the risk factors in the Company's most recent annual management'sdiscussion and analysis that is available on the Company's profile onSEDAR at www.sedar.com. Readers are cautioned that theforegoing list of factors is not exhaustive. The forward-lookingstatements included in this news release are expressly qualified bythis cautionary statement. The forward-looking statements andinformation contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether becauseof new information, future events or otherwise, unless so required byapplicable securities laws.

Copyright (c) 2025 TheNewswire - All rights reserved.

[Reuters](https://www.tradingview.com/news/reuters.com,2025-02-11:newsml_Tnw3GNW8P:0-ventripoint-issues-option-grants-and-reports-exercise-of-options/)
